Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000233990

Medchemexpress LLC CB1 inverse agonist 2 | 1019839-52-1 | 99.2% | 5 MG
SDP

Catalog No. 5000233990
Encompass_Preferred

CB1 inverse agonist 2 is an orally active inverse agonist of the cannabinoid CB1 receptor shown to inhibit CP55940-induced hypothermia and anorexia in mouse models. Supplied at high purity for research applications, it is appropriate for preclinical studies and small-scale pharmacology work.

  • Orally active CB1 receptor inverse agonist.
  • Demonstrated efficacy against CP55940-induced hypothermia and anorexia in mice.
  • High purity suitable for research use.
  • Molecular formula C24H20ClFN2OS and molecular weight 438.94 g/mol.
  • Available in small quantities for preclinical and exploratory studies.

Catalog No. 50-002-33990 Supplier Medchemexpress LLC Supplier No. HY120955MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

CB1 inverse agonist 2 is an orally active inverse agonist of the cannabinoid CB1 receptor shown to inhibit CP55940-induced hypothermia and anorexia in mouse models. Supplied at high purity for research applications, it is appropriate for preclinical studies and small-scale pharmacology work.

  • Orally active CB1 receptor inverse agonist.
  • Demonstrated efficacy against CP55940-induced hypothermia and anorexia in mice.
  • High purity suitable for research use.
  • Molecular formula C24H20ClFN2OS and molecular weight 438.94 g/mol.
  • Available in small quantities for preclinical and exploratory studies.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.